News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlphaMed Release: New Method to Produce Blood Cells From Stem Cells Could Yield a Purer, Safer Cell Therapy



7/12/2013 9:18:38 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Durham, NC – A new protocol for reprogramming induced pluripotent stem cells (iPSCs) into mature blood cells, using just a small amount of the patient’s own blood and a readily available cell type, is reported on in the current issue of STEM CELLS Translational Medicine. This novel method skips the generally accepted process of mixing iPSCs with either mouse or human stromal cells during the differentiation process and, in essence, ensures no outside and potentially harmful DNA is introduced into the reprogrammed cells.

As such, it could lead to a purer, safer therapeutic grade of stem cells for use in regenerative medicine.

The discovery of iPSCs holds great promise for regenerative medicine since it is possible to produce patient-specific iPSCs from the individual for potential autologous treatment — that is, treatment using the patient’s own cells. This avoids the possibility of rejection and numerous other harmful side effects.

CD34+ cells are a type of blood stem cell that has been linked to proliferation. However, collecting enough CD34+ cells from a patient to produce an adequate amount of blood usually requires a large volume of blood to be taken from the patient. But scientists found a way around this, as outlined in the new study conducted by researchers in the Department of Medicine and Institute for Human Genetic, University of California-San Francisco. They were led by Yuet Wai Kan, M.D., FRS, and Lin Ye, Ph.D.

“We used Sendai viral vectors to generate iPSCs efficiently from adult mobilized CD34+ and peripheral blood mononuclear cells (MNCs),” Dr. Kan explained. “Sendai virus is an RNA virus that carries no risk of altering the host genome, so is considered an efficient solution for generating safe iPSC.”

“Just 2 milliliters of blood yielded iPS cells from which hematopoietic stem and progenitor cells could be generated. These cells could contain up to 40 percent CD34+ cells, of which approximately 25 percent were the type of precursors that could be differentiated into mature blood cells. These interesting findings reveal a protocol for the generation iPSCs using a readily available cell type,” Dr. Ye added. “We also found that MNCs can be efficiently reprogrammed into iPSCs as readily as CD34+ cells. Furthermore, these MNCs derived iPSCs can be terminally differentiated into mature blood cells.”

“This method, which uses only a small blood sample, may represent an option for generating iPSCs that maintains their genomic integrity,” said Anthony Atala, MD, Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The fact that these cells were differentiated into mature blood cells suggests their use in blood diseases.”

The full article, “Blood cell derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (www.StemCells.com), in its 31th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, in its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES